Positive and strongly positive rates of SERPIND1 expression were reported for the malignant group (90.40 and 67.20%, respectively), the malignant group included 77 serous carcinomas, 18 mucinous carcinomas, 8 endometrioid carcinomas, and 10 clear-cell carcinomas. The gene discussed is SERPIND1; the disease is serous adenocarcinoma.